

BRISTOL MYERS SQUIBB CO

Form 8-K

November 08, 2004

**Table of Contents**

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934**

Date of Report (Date of earliest event reported): November 2, 2004

**BRISTOL-MYERS SQUIBB COMPANY**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other  
Jurisdiction of  
Incorporation)

**1-1136**  
(Commission File  
Number)

**22-079-0350**  
(IRS Employer  
Identification  
Number)

345 Park Avenue  
New York, NY, 10154  
(Address of Principal Executive Office)

Registrant's telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
- 
-

**TABLE OF CONTENTS**

Item 1.01. Amendment to a Material Definitive Agreement.

SIGNATURES

---

**Table of Contents**

**Item 1.01. Amendment to a Material Definitive Agreement.**

On November 2, 2004, the vesting of 178,889 shares of restricted stock previously awarded to James Palmer, former Chief Scientific Officer were accelerated pursuant to a decision by the Compensation and Management Development Committee following Dr. Palmer's death. In addition, the Compensation and Management Development Committee granted Dr. Palmer full-term participation of Long-Term Performance Awards previously granted to him.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bristol-Myers Squibb Company

Date: November 8, 2004

BY: /s/ Sandra Leung

\_\_\_\_\_  
Name: Sandra Leung

Title: Secretary